Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Clinical Studies and Outcomes in Urologic Cancer
share announcement

Clinical Studies and Outcomes in Urologic Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 1097

Special Issue Editor

Dr. Nikolaos Pyrgidis

E-Mail Website
Guest Editor
Department of Urology, LMU University Hospital, LMU Munich, 81377 Munich, Germany
Interests: urologic oncology; prostate cancer; bladder cancer

Special Issue Information

Dear Colleagues,

We are excited to announce a Special Issue focusing on clinical studies and outcomes in urologic cancer. This Special Issue will address the critical advances, challenges, and insights in the management of urologic cancers, especially the clinical outcomes associated with evolving therapies and interventions. Urologic cancers, including prostate, urothelial, and kidney cancer, continue to pose significant clinical and research challenges, making it essential to understand better their trends, treatment responses, and long-term patient outcomes.

This Special Issue aims to gather high-quality clinical studies and reviews that contribute to a comprehensive understanding of urologic cancer care. We seek to highlight innovative research that examines operative complications, survival outcomes, recurrence rates, quality of life, and novel therapeutic approaches, contributing to the journal’s commitment to advancing knowledge in oncology and urology. Original research articles and comprehensive reviews that fit within these themes (but are not limited to them) are welcomed.

We look forward to receiving your contributions and showcasing cutting-edge research in this pivotal area.

Dr. Nikolaos Pyrgidis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urologic cancer
  • clinical outcomes
  • prostate cancer
  • urothelial cancer
  • kidney cancer
  • survival analysis
  • treatment response
  • quality of life
  • novel therapies
  • oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 530 KiB  
Article
Perioperative Outcomes After Radical Nephrectomy with Inferior Vena Cava Thrombectomy
by Nikolaos Pyrgidis, Gerald Bastian Schulz, Christian G. Stief, Iulia Blajan, Troya Ivanova, Annabel Graser and Michael Staehler
Cancers 2025, 17(7), 1083; https://doi.org/10.3390/cancers17071083 - 24 Mar 2025
Viewed by 316
Abstract
Background and Objective: We aimed to evaluate current trends and complications after radical nephrectomy with inferior vena cava (IVC) thrombectomy and to provide evidence on the role of the annual hospital caseload on perioperative outcomes. Methods: We used the GeRmAn Nationwide inpatient Data [...] Read more.
Background and Objective: We aimed to evaluate current trends and complications after radical nephrectomy with inferior vena cava (IVC) thrombectomy and to provide evidence on the role of the annual hospital caseload on perioperative outcomes. Methods: We used the GeRmAn Nationwide inpatient Data (GRAND), provided by the German Bureau of Statistics (2005–2022). All hospitals performing radical nephrectomy with IVC thrombectomy were subclassified based on their annual caseload to low- (<3 cases/year), intermediate- (3–9 cases/year), and high-volume centers (≥10 cases/year). We included 3608 patients. Key Findings and Limitations: Overall, 1880 (52%) patients underwent surgery in low-, 1466 (40%) in intermediate-, and 848 (8%) in high-volume centers. Most patients (3574, 99%) underwent open surgery. The number of patients undergoing radical nephrectomy with IVC thrombectomy has decreased in the last years. Patients undergoing surgery in low-, intermediate- and high-volume centers had similar baseline characteristics. Operation in high-volume centers, compared to low-volume centers, was associated with lower odds of intensive care unit admission (29% versus 45%, OR: 0.5, 95% CI: 0.4–0.7, p < 0.001) and a shorter hospital stay by 3.9 days (95% CI: 2.2–5.6, p < 0.001). Importantly, for every additional case performed annually, hospitals improve their perioperative outcomes in terms of mortality (p = 0.032), intensive care unit admissions (p = 0.002), acute kidney disease (p = 0.029), and length of hospital stay (p < 0.001). Conclusions and Clinical Implications: The present real-world data demonstrate that, for every additional case performed annually, hospitals improve their perioperative outcomes in terms of major perioperative complications. Full article
(This article belongs to the Special Issue Clinical Studies and Outcomes in Urologic Cancer)
►▼ Show Figures

Figure 1

17 pages, 1035 KiB  
Article
Improving Risk Stratification in pT3 Upper Tract Urothelial Carcinoma: A Focus on Invasion Patterns
by Yung-Tai Chen, Hsiang-Ying Lee, Wen-Jeng Wu, Chih-Hung Lin, Yuan-Hong Jiang, Yu-Khun Lee, Kuan-Hsun Huang and Yao-Chou Tsai
Cancers 2025, 17(6), 923; https://doi.org/10.3390/cancers17060923 - 8 Mar 2025
Viewed by 541
Abstract
Purpose: Existing T3 subclassifications for upper tract urothelial cancer (UTUC) are limited by heterogeneity and a primary focus on renal pelvis tumors. Our study aimed to propose a novel pT3 subclassification system specifically tailored to pT3 UTUC patients. Materials and Methods: This study [...] Read more.
Purpose: Existing T3 subclassifications for upper tract urothelial cancer (UTUC) are limited by heterogeneity and a primary focus on renal pelvis tumors. Our study aimed to propose a novel pT3 subclassification system specifically tailored to pT3 UTUC patients. Materials and Methods: This study analyzed 120 pT3 UTUC cases from a Taiwanese multicenter registry, using a standardized pathology report and a single pathologist for evaluation. Results: Univariate analysis revealed survival differences based on existing subclassifications. Multivariate analysis identified concurrent fat and parenchyma invasion as an independent predictor of worse overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Conclusions: This study proposes a novel pT3 subclassification incorporating fat and parenchyma invasion, applicable to all UTUC sites. This subclassification may improve risk stratification, guide treatment decisions, and ultimately enhance patient outcomes. Full article
(This article belongs to the Special Issue Clinical Studies and Outcomes in Urologic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop